Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Angeles Alvarez Secord, MD, discusses the risk of recurrence of ovarian cancer with her patient, Michelle Berke. Dr Secord also explains how BRCA mutations play a role in the disease course and how she determines the best treatment option once cancer recurs.
Angeles Alvarez Secord, MD, revisits her initial conversations about surgery and chemotherapy with her patient, Michelle Berke, following Michelle’s ovarian cancer diagnosis. They also discuss decisions regarding maintenance therapy.
Michelle Berke talks with Angeles Alvarez Secord, MD, about the symptoms she experienced leading up to her ovarian cancer diagnosis. Dr. Secord provides guidance on the signs and symptoms that women should not ignore.
Anya Khomenko reflects on her journey as a patient and survivor of ovarian cancer and suggests why patients need to advocate for themselves and remain positive that there are always new treatment options on the horizon.
Justin Chura, MD, discusses his initial approach to treating ovarian cancer. Anya Khomenko, survivor of ovarian cancer, advises patients on how to become educated on new therapeutic options and prepare for follow-up appointments.